Earlier valve replacement benefits some patients with moderate aortic stenosis

by Kristin Reynolds, Cedars-Sinai Medical Center

edited by Sadie Harley, reviewed by Robert Egan

Sadie Harley

Scientific Editor

Meet our editorial team
Behind our editorial process

Robert Egan

Senior Editor

Meet our editorial team
Behind our editorial process Editors' notes

This article has been reviewed according to Science X's editorial process and policies. Editors have highlighted the following attributes while ensuring the content's credibility:

fact-checked

peer-reviewed publication

trusted source

proofread

The GIST Add to Preferred Sources

Patients with moderate aortic stenosis, a narrowing of the heart's aortic valve, may benefit from undergoing transcatheter aortic valve replacement (TAVR) before the disease becomes severe, according to findings from a clinical trial co-led by Cedars-Sinai investigators.

The study found that earlier TAVR treatment lowered the combined risk of death or a heart-failure event over two years in certain patients with moderate aortic stenosis.

Findings from the PROGRESS clinical trial were published in The New England Journal of Medicine and presented at the Transcatheter Cardiovascular Therapeutics (TCT) 2026 symposium in San Diego.

Raj Makkar, M.D., vice president of cardiovascular innovation and intervention in the Smidt Heart Institute at Cedars-Sinai, is the national principal investigator for the trial.

Earlier treatment reduces heart-failure events

The benefit of earlier treatment was shown by patients experiencing fewer heart-failure events, including hospitalizations, Makkar said.

"Patients with moderate aortic stenosis can already have symptoms and signs that their heart is under strain. These results show that for selected patients with at-risk features, treating the valve earlier can reduce the risk of heart-failure events before the narrowing becomes severe."

The Smidt Heart Institute at Cedars-Sinai enrolled more patients than any other participating center, giving patients a key role in advancing research into the disease.

"Our extensive experience with treating valvular heart disease, along with our ability to integrate research into routine patient care, powered our ability to enroll a significant number of patients," said Makkar, the Karsh Distinguished Chair in Interventional Cardiology.

Testing intervention before stenosis becomes severe

Aortic stenosis, which reduces blood flow from the heart to the body, affects more than 3% of adults 65 and older. Current guidelines recommend an echocardiogram every one to two years in patients with moderate disease, and valve replacement only when the stenosis becomes severe or another indication for surgery develops.

The PROGRESS trial enrolled 744 patients 65 or older at 74 centers in six countries. All had moderate aortic stenosis and at least one feature indicating increased risk, such as symptoms or abnormalities in heart structure or function. Investigators randomly assigned 373 patients to TAVR and 371 to clinical surveillance, with valve replacement available when indicated.

After two years, 23.9% of those assigned to surveillance had experienced heart failure or died, compared with 16.7% of patients assigned to TAVR. Patients who underwent TAVR were hospitalized for heart failure at half the rate of surveillance patients: 7.4% compared with 14.9% of those in the surveillance group.

"More than half of the patients initially assigned to surveillance underwent valve replacement within two years, suggesting that the disease can progress quickly from moderate to severe in some patients," said Aakriti Gupta, M.D., study co-author and an assistant professor in the Smidt Heart Institute.

Long-term benefits remain under study

The findings do not mean that every patient with moderate aortic stenosis should undergo TAVR. Researchers plan to follow participants for 10 years to determine whether the early reduction in heart-failure events translates into longer survival. They also will assess valve durability, the potential need for future procedures and which patients are most likely to benefit.

Because participants were an average of 78 years old, researchers also will examine whether the findings apply to younger patients or those without the at-risk features studied in PROGRESS.

"Helping patients avoid heart-failure episodes and the hospital stays that come with them is an important goal," said Eduardo Marbán, M.D., Ph.D., executive director of the Smidt Heart Institute and the Mark Siegel Family Foundation Distinguished Chair.

"As an institution that is well positioned to treat the most complex heart valve cases, we are grateful to our patients, who were willing to participate in a clinical trial to help answer a question that could improve care for others."

Publication details

Philippe Généreux et al., TAVR in Patients with Moderate Aortic Stenosis with At-Risk Features, New England Journal of Medicine (2026). DOI: 10.1056/nejmoa2607326

Journal information: New England Journal of Medicine

Key medical concepts

Transcatheter Aortic Valve ReplacementDeath

Clinical categories

CardiologyCommon illnesses & PreventionHealthy aging Provided by Cedars-Sinai Medical Center Who's behind this story?

Sadie Harley

BSc Life Sciences & Ecology. Microbiology lab background with pharmaceutical news experience in oil, gas, and renewable industries. Full profile →

Robert Egan

Bachelor's in mathematical biology, Master's in creative writing. Well-traveled with unique perspectives on science and language. Full profile →

Citation: Earlier valve replacement benefits some patients with moderate aortic stenosis (2026, November 3) retrieved 3 November 2026 from https://medicalxpress.com/news/2026-11-earlier-valve-benefits-patients-moderate.html This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.